Results 201 to 210 of about 246,176 (312)

A 52‐week open‐label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To assess the safety, tolerability, and treatment effects of rimegepant 75 mg every other calendar day (EOD) for the preventive treatment of migraine in a 52‐week, open‐label extension (OLE) study. Background Rimegepant is an oral small molecule calcitonin gene–related peptide receptor antagonist approved for the acute treatment of ...
David Kudrow, Robert S. Croop, Alexandra Thiry, Richard B. Lipton   +3 more
wiley   +1 more source

Treatment effectiveness of galcanezumab versus traditional oral migraine preventive medications at 3 months: Results from the TRIUMPH study

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective This study assesses the 3‐month effectiveness of the calcitonin gene‐related peptide monoclonal antibody galcanezumab versus traditional oral migraine preventive medications. Background Studies comparing the effectiveness of calcitonin gene‐related peptide monoclonal antibodies versus traditional oral migraine preventive medications ...
Richard B. Lipton, Miguel J. A. Láinez, Zubair Ahmed, Carlos Vallarino, Diego Novick, Maurice Vincent, Lars Viktrup, Rebecca L. Robinson   +7 more
wiley   +1 more source

ALBERT EINSTEIN

Science and Culture
  +5 more sources

Una fórmula de Albert Einstein, trabajo + juego + silencio = éxito : es un merengue 8

, 1988
Gloria Elena Monsalve, Margaritainés Restrepo Santamaría   +1 more
openalex   +1 more source

OnabotulinumtoxinA treatment among diverse racial groups: Post hoc analysis of the phase 4 Chronic migraine OnabotulinuMtoxinA Prolonged Efficacy open‐Label (COMPEL) trial

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective Examine treatment responses to and safety of onabotulinumtoxinA for the preventive treatment of chronic migraine (CM) among diverse racial groups. Background Evidence suggests there are differences in headache treatment patterns, symptom profiles, and burden based on race.
Andrew M. Blumenfeld, Larry Charleston IV, Deena Kuruvilla, Belinda Savage‐Edwards, Richard B. Lipton, Ritu Singh, Patricia Jacob, Nicole A. Lawrence, Cuiwei Wang, Hope L. O'Brien   +9 more
wiley   +1 more source

La teoria del conocimiento de albert einstein

, 1980
J.A Serrano
openalex   +1 more source

Waves on the Isis: Albert Einstein and Erwin Schrödinger in Oxford

Andrew Robinson
openalex   +1 more source

FERNÁNDEZ BUEY, Francisco. Albert Einstein : ciencia y conciencia

, 2007
Jon Arrizabalaga
openalex   +2 more sources

Reasons for patient reluctance to take preventive medications for migraine: Results of the OVERCOME (US) study

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objectives/Background This study was undertaken to evaluate patient reasons for nonadoption of migraine‐preventive medications. Despite clear recommendations and eligibility criteria for migraine‐preventive treatment by the American Headache Society and the availability of these treatments, many people with migraine are not taking appropriate ...
Jessica Ailani, Rose Okonkwo, Elizabeth Johnston, Helen Hochstetler, Betzaida Martinez, Anthony Zagar, Robert A. Nicholson, Bert B. Vargas, E. Jolanda Muenzel, Richard B. Lipton   +9 more
wiley   +1 more source

AFilosofia da Ciência de Albert Einstein

Vinícius Carvalho da Silva, Larissa Vargas de Freitas, M. Begalli   +2 more
openalex   +2 more sources